The Effect of 0.5% Roxithromycin Lotion for Androgenetic Alopecia
This trial is active, not recruiting.
|Start date||May 2005|
|End date||January 2007|
|Trial size||20 participants|
|Trial identifier||NCT00197379, 16-61|
The purpose of this study is exploiting the new drugs for androgenetic alopecia because there are still no effective and safe topical drug for androgenetic alopecia. Roxithomycin is one of the macrolide antibiotics that has immunomodulatory effects. We firstly found that roxithromycin increases the rate of murine and human hair follicle elongation in vitro. Therefore, we apply this drug on this disease therapy.
|Endpoint classification||safety/efficacy study|
|Intervention model||crossover assignment|
Pathological study taken from lesional scalp skin.
time frame: One year
Male or female participants at least 20 years old.
Inclusion Criteria: - Androgenetic alopecia Exclusion Criteria: - Cicatricial alopecia - Allergy to roxitromycin - Children (19years old or younger) - Pregnant female
|Official title||The Study for New Effect of Roxithromycin on Androgenetic Alopecia.|
|Description||The topical therapy for androgenetic alopecia is still not enough to improve cosmetically. Thereforem we try to find new effective and safe topical therapy for this disease. Roxithromycin has not only antibacterial action but also immunomodulatory and anti-inflamatory potency. For example, roxitromycin inhibits T cell responces to mitogens and production of cytokines, IL-2 and IL-5. We firstly found that roxitromycin increased human and murine hair elongation in vitro to inhibit apoptosis of hair bulb. Then, we wish to apply roxithromycin on the therapy for androgenetic alopecia.|
Call for more information